Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Omeros -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (449)	2/14/2018 2:26:18 PM
From: scaram(o)uche	Read Replies (2) \| Respond to of 464

I haven't been a shareholder. Just bought a small stake. Greg has over promised under delivered since about forever. The guy has serious issues. But everyone knew about the debt, and everyone knew that Omidria pass through was max'd. It was clearly specified when the designation was issued. So I really don't know why Feuerstein is crowing. OTOH, company promised profit on O's back. Seemed laughable, was. Add eons of gpcr-baiting, and omer is easy to under estimate. So.... FourWorld picked fostamatinib as the big-time 721 competitor? Snicker. >> Patient enrollment is expected to begin early next month << That's like right about now, give or take?